Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Case Reports
Share your love
Brim Biotech’s Clinical Trial for DED Kicks Off
BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease (DED) and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients with moderate…
Link Between Antioxidant Supplements and Late-Stage Dry AMD
In a significant development for the treatment of late-stage dry age-related macular degeneration (AMD), researchers at the National Institutes of Health (NIH) have identified that daily antioxidant supplements can potentially slow the progression of the disease, preserving central vision for…
Opus Genetics Receives FDA RPD Designation for OPGx-LCA5
Research Triangle Park, N.C. – August 20, 2024 – Opus Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for its ocular gene therapy, OPGx-LCA5, which aims to treat patients with…
FDA Notifies Ocugen to Begin Expanded Access Program RP
The FDA has authorized Ocugen, Inc. to launch an expanded access program (EAP) for patients aged 18 and older with retinitis pigmentosa (RP), providing early access to its promising gene therapy candidate, OCU400. The treatment has shown encouraging results in…
Bausch + Lomb’s TENEO Laser Achieves Strong LASIK Outcomes
Bausch + Lomb recently published the results of a pivotal clinical trial for its TENEO™ Excimer Laser in the Journal of Refractive Surgery. This study, which played a crucial role in securing U.S. FDA approval for the device in January…
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Okyo Pharma’s Phase 2 Trial for Neuropathic Corneal Pain
Okyo Pharma announced its plan to initiate a phase 2 clinical trial for OK-101 in the treatment of neuropathic corneal pain (NCP), scheduled to begin in the third quarter of 2024. This one-year study follows promising results from preclinical animal…
NexThera Submits IND Application for NT-101 for Wet AMD
NexThera has officially submitted a Phase 1/2a Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NT-101, an innovative non-invasive eye drop treatment targeting wet age-related macular degeneration (wet AMD). Proprietary Delivery Platform: Advancing Treatment…
Funding Boost for PulseMedica’s Eye Floater Technology
PulseMedica has successfully raised a total of $12 million in their recent pre-Series A financing round, marking a significant milestone in their pursuit of innovative eye floater diagnostic and treatment technologies. Accelerating Clinical Validation and Expansion Efforts This funding round…
FDA Clears Enhanced SPECTRALIS® OCTA Module by Heidelberg
Heidelberg Engineering announced the FDA clearance of its upgraded SPECTRALIS® OCTA Module featuring SHIFT technology. This advancement promises to significantly reduce acquisition time by 50%, marking a pivotal development in clinical efficiency and diagnostic precision within ophthalmology. Enhancing Clinical Utility…